Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

3.3K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
3.3K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

15.0K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
15.0K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

6.4K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.4K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

930
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
930
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

373
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
373
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

2.1K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiomics studies reveal how ambient temperature changes govern cellular responses of Chlamydomonas.

The Plant cell·2026
Same author

Development of DPP-4-resistant CXCL9-Fc and CXCL10-Fc chemokines for effective cancer immunotherapy.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Metamorphosis of a unicellular green alga in the presence of acetate and a spatially structured three-dimensional environment.

The New phytologist·2024
Same author

PD-1 and CTLA-4 serve as major gatekeepers for effector and cytotoxic T-cell potentiation by limiting a CXCL9/10-CXCR3-IFNγ positive feedback loop.

Frontiers in immunology·2024
Same author

Crosstalk between bone metastatic cancer cells and sensory nerves in bone metastatic progression.

Life science alliance·2024
Same author

Glycerol Trinitrate Acts Downstream of Calcitonin Gene-Related Peptide in Trigeminal Nociception-Evidence from Rodent Experiments with Anti-CGRP Antibody Fremanezumab.

Cells·2024

Related Experiment Video

Updated: Nov 16, 2025

Investigating Migraine-Like Behavior Using Light Aversion in Mice
05:23

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

4.2K

Migraine therapeutics differentially modulate the CGRP pathway.

Minoti Bhakta1, Trang Vuong1, Tetsuya Taura1

  • 1Teva Biologics, Redwood City, CA, USA.

Cephalalgia : an International Journal of Headache
|February 25, 2021
PubMed
Summary
This summary is machine-generated.

Comparing calcitonin-gene related peptide (CGRP) pathway migraine treatments reveals distinct mechanisms. Antibodies and small molecules targeting the CGRP receptor or ligand show varied efficacy and receptor interactions, potentially impacting patient outcomes.

Keywords:
AMY1CGRPerenumabfremanezumabgepantmigraine

More Related Videos

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents
08:39

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents

Published on: May 16, 2022

2.7K
Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
05:49

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

1.1K

Related Experiment Videos

Last Updated: Nov 16, 2025

Investigating Migraine-Like Behavior Using Light Aversion in Mice
05:23

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

4.2K
Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents
08:39

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents

Published on: May 16, 2022

2.7K
Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
05:49

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

1.1K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Molecular Biology

Background:

  • The calcitonin-gene related peptide (CGRP) pathway is crucial in migraine pathogenesis.
  • Approved migraine therapeutics include antibodies targeting CGRP or its receptor, and small molecule CGRP receptor antagonists.
  • A comparative analysis of the mechanisms of action for these CGRP pathway agents is needed.

Purpose of the Study:

  • To compare the mechanisms of action of a CGRP ligand antibody (fremanezumab), a CGRP receptor antibody (erenumab), and a CGRP receptor small molecule antagonist (telcagepant).
  • To investigate potential differences in binding, functional activity, and cellular internalization among these CGRP pathway therapeutics.

Main Methods:

  • Utilized binding assays, functional assays measuring cAMP signaling, and imaging assays.
  • Compared the effects of fremanezumab, erenumab, and telcagepant on human CGRP and CGRP receptor family member (AMY1) signaling.
  • Assessed receptor binding and internalization for erenumab and fremanezumab.

Main Results:

  • Erenumab and telcagepant antagonized CGRP, adrenomedullin, and intermedin signaling at the CGRP receptor, and also amylin signaling at the AMY1 receptor.
  • Fremanezumab selectively antagonized CGRP-induced signaling at the CGRP receptor but did not affect amylin responses or signaling at AMY1.
  • Erenumab, unlike fremanezumab, bound and internalized at the CGRP receptor and also at the AMY1 receptor.

Conclusions:

  • Therapeutic agents targeting the CGRP ligand versus the CGRP receptor may exert distinct mechanisms of action.
  • These mechanistic differences could influence the efficacy, safety, and tolerability profiles of CGRP pathway therapeutics in migraine patients.
  • Further research is warranted to elucidate the full clinical implications of these varied mechanisms.